UBS has released a research report stating that CANSINOBIO's (06185) first-quarter performance for the year met expectations. During the period, revenue reached 190 million yuan, representing a year-on-year increase of 38.7%, slightly surpassing the bank's forecast of 34% growth for the full year 2026. The net loss was 40 million yuan, compared to the bank's full-year 2024 profit forecast of 337 million yuan. UBS adjusted its earnings per share forecasts for the group for 2026 to 2028, revising them down from the original 1.36 yuan, 2.26 yuan, and 3.77 yuan to 0.77 yuan, 2.15 yuan, and 3.58 yuan, respectively. The target price was reduced from HK$59.8 to HK$52.4, while maintaining a "Buy" rating.